Will Opdivo bring new turning point in treating lung cancer?

Published: 2016-04-19 11:02:47

Updated: 2016-04-19 11:02:47

Opdivo has attracted interests if it could bring a new paradigm in treating lung cancer through acquiring the first domestic approval as a non-small cell lung cancer immune antibody.

Ono Pharma(CEO Ito Kynihiko) and BMS Pharmaceutical Korea(CEO Hye-sun Park) held a press conference on the 15^th and introduced major clinical trials and expectations on them.

Opdivo was approved as a secondary ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.